Year |
Citation |
Score |
2009 |
Zeng Q, Phukan S, Xu Y, Sadim M, Rosman DS, Pennison M, Liao J, Yang GY, Huang CC, Valle L, Di Cristofano A, de la Chapelle A, Pasche B. Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development. Cancer Research. 69: 678-86. PMID 19147584 DOI: 10.1158/0008-5472.Can-08-3980 |
0.612 |
|
2008 |
Rosman DS, Phukan S, Huang CC, Pasche B. TGFBR1*6A enhances the migration and invasion of MCF-7 breast cancer cells through RhoA activation. Cancer Research. 68: 1319-28. PMID 18316594 DOI: 10.1158/0008-5472.Can-07-5424 |
0.667 |
|
2007 |
Rosman DS, Kaklamani V, Pasche B. New insights into breast cancer genetics and impact on patient management. Current Treatment Options in Oncology. 8: 61-73. PMID 17634833 DOI: 10.1007/S11864-007-0021-5 |
0.61 |
|
2006 |
Kaklamani VG, Baddi L, Liu J, Rosman D, Phukan S, Bradley C, Hegarty C, McDaniel B, Rademaker A, Oddoux C, Ostrer H, Michel LS, Huang H, Chen Y, Ahsan H, et al. Erratum: Combined genetic assessment of transforming growth factor-β signaling pathway variants may predict breast cancer risk (Cancer Research (April 15, 2005) 65 (3454-3461)) Cancer Research. 66. DOI: 10.1158/0008-5472.Can-66-6-Cor |
0.637 |
|
2005 |
Pasche B, Knobloch T, Bian Y, Liu J, Kaklamani V, Baddi L, Rosman D, de la Chapelle A, Weghorst C. TGFBR1*6A is somatically acquired at high frequency in cancer and switches TGF-β responses. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 9511. PMID 27946718 DOI: 10.1200/Jco.2005.23.16_Suppl.9511 |
0.672 |
|
2005 |
Pasche B, Knobloch TJ, Bian Y, Liu J, Phukan S, Rosman D, Kaklamani V, Baddi L, Siddiqui FS, Frankel W, Prior TW, Schuller DE, Agrawal A, Lang J, Dolan ME, et al. Somatic acquisition and signaling of TGFBR1*6A in cancer. Jama. 294: 1634-46. PMID 16204663 DOI: 10.1001/Jama.294.13.1634 |
0.708 |
|
2005 |
Kaklamani VG, Baddi L, Liu J, Rosman D, Phukan S, Bradley C, Hegarty C, McDaniel B, Rademaker A, Oddoux C, Ostrer H, Michel LS, Huang H, Chen Y, Ahsan H, et al. Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Cancer Research. 65: 3454-61. PMID 15833881 DOI: 10.1158/0008-5472.Can-04-2961 |
0.677 |
|
2004 |
Kaklamani V, Baddi L, Rosman D, Liu J, Ellis N, Oddoux C, Ostrer H, Chen Y, Ahsan H, Offit K, Pasche B. No major association between TGFBR1*6A and prostate cancer. Bmc Genetics. 5: 28. PMID 15385056 DOI: 10.1186/1471-2156-5-28 |
0.646 |
|
Show low-probability matches. |